Richard Callaghan

8.6k total citations · 1 hit paper
130 papers, 6.8k citations indexed

About

Richard Callaghan is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Richard Callaghan has authored 130 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 54 papers in Molecular Biology and 16 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Richard Callaghan's work include Drug Transport and Resistance Mechanisms (71 papers), Pharmacological Effects and Toxicity Studies (16 papers) and Maritime and Coastal Archaeology (14 papers). Richard Callaghan is often cited by papers focused on Drug Transport and Resistance Mechanisms (71 papers), Pharmacological Effects and Toxicity Studies (16 papers) and Maritime and Coastal Archaeology (14 papers). Richard Callaghan collaborates with scholars based in United Kingdom, Australia and Canada. Richard Callaghan's co-authors include Christopher F. Higgins, Howard R. Mellor, Robert C. Ford, Catherine Martin, Matthew D. Hall, Ian D. Kerr, Szabolcs Modok, Mark F. Rosenberg, G. Berridge and Trevor W. Hambley and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Richard Callaghan

130 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Global Origins and Development of Seafaring

2011 188 citations Richard Callaghan profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Callaghan United Kingdom	44	4.3k	2.8k	1.1k	799	522	130	6.8k
I. David Goldman United States	55	2.2k 0.5×	4.1k 1.4×	1.1k 1.0×	605 0.8×	365 0.7×	212	10.9k
Ming‐Daw Tsai United States	51	1.1k 0.3×	7.5k 2.6×	83 0.1×	427 0.5×	663 1.3×	292	10.1k
Theodore Peters United States	43	1.6k 0.4×	5.9k 2.1×	392 0.3×	76 0.1×	881 1.7×	108	10.3k
Jeremy M Berg United States	58	1.6k 0.4×	7.9k 2.8×	78 0.1×	366 0.5×	1.1k 2.1×	299	13.4k
Awtar Krishan United States	39	1.6k 0.4×	3.2k 1.1×	180 0.2×	143 0.2×	322 0.6×	169	6.0k
Takehiro Suzuki Japan	43	851 0.2×	4.7k 1.7×	396 0.4×	123 0.2×	360 0.7×	274	7.5k
Joseph R. Casey Canada	46	297 0.1×	4.7k 1.7×	464 0.4×	157 0.2×	470 0.9×	128	7.8k
Massimo Coletta Italy	43	537 0.1×	3.9k 1.4×	707 0.6×	204 0.3×	264 0.5×	316	7.0k
Lucy M. Anderson United States	35	898 0.2×	2.3k 0.8×	425 0.4×	327 0.4×	101 0.2×	177	5.1k
Piero Pucci Italy	47	673 0.2×	4.6k 1.6×	103 0.1×	134 0.2×	281 0.5×	297	8.3k

Countries citing papers authored by Richard Callaghan

Since Specialization

Citations

This map shows the geographic impact of Richard Callaghan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Callaghan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Callaghan more than expected).

Fields of papers citing papers by Richard Callaghan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Callaghan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Callaghan. The network helps show where Richard Callaghan may publish in the future.

Co-authorship network of co-authors of Richard Callaghan

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Callaghan. A scholar is included among the top collaborators of Richard Callaghan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Callaghan. Richard Callaghan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Callaghan, Richard, et al.. (2022). Regulation of P-Glycoprotein in the Brain. International Journal of Molecular Sciences. 23(23). 14667–14667. 46 indexed citations

Callaghan, Richard, et al.. (2022). The Ubiquitin E3 Ligase Nedd4 Regulates the Expression and Amyloid-β Peptide Export Activity of P-Glycoprotein. International Journal of Molecular Sciences. 23(3). 1019–1019. 9 indexed citations

Briggs, Deborah A., et al.. (2022). Vinca alkaloid binding to P-glycoprotein occurs in a processive manner. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1864(10). 184005–184005. 7 indexed citations

Devine, Shane M., Richard Callaghan, Michel O. Steinmetz, et al.. (2021). 1,3‐Benzodioxole‐Modified Noscapine Analogues: Synthesis, Antiproliferative Activity, and Tubulin‐Bound Structure. ChemMedChem. 16(18). 2882–2894. 11 indexed citations

Souza, David P. De, Dedreia Tull, Malcolm J. McConville, et al.. (2021). The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence. The International Journal of Biochemistry & Cell Biology. 133. 105935–105935. 3 indexed citations

Devine, Shane M., et al.. (2019). A Novel Class of N‐Sulfonyl and N‐Sulfamoyl Noscapine Derivatives that Promote Mitotic Arrest in Cancer Cells. ChemMedChem. 14(23). 1968–1981. 10 indexed citations

Yuan, Ying, Tao Cai, Richard Callaghan, et al.. (2019). Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells. SHILAP Revista de lepidopterología. 1 indexed citations

Devine, Shane M., Luigi Aurelio, Colin W. Pouton, et al.. (2018). Synthesis and Pharmacological Evaluation of Noscapine-Inspired 5-Substituted Tetrahydroisoquinolines as Cytotoxic Agents. Journal of Medicinal Chemistry. 61(18). 8444–8456. 20 indexed citations

DeBono, Aaron, et al.. (2018). Overcoming P-Glycoprotein–Mediated Drug Resistance with Noscapine Derivatives. Drug Metabolism and Disposition. 47(2). 164–172. 17 indexed citations

10.

Board, Mary, et al.. (2016). The Effects of Severe Hypoxia on Glycolytic Flux and Enzyme Activity in a Model of Solid Tumors. Journal of Cellular Biochemistry. 117(8). 1890–1901. 28 indexed citations

11.

Jeyabalan, Jeshmi, M. Andrew Nesbit, Juris Galvanovskis, et al.. (2010). SEDLIN Forms Homodimers: Characterisation of SEDLIN Mutations and Their Interactions with Transcription Factors MBP1, PITX1 and SF1. PLoS ONE. 5(5). e10646–e10646. 21 indexed citations

12.

Modok, Szabolcs, Richard T. Scott, Rebecca A. Alderden, et al.. (2007). Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model. British Journal of Cancer. 97(2). 194–200. 28 indexed citations

13.

McDevitt, Christopher A., Richard F. Collins, Michael Conway, et al.. (2006). Purification and 3D Structural Analysis of Oligomeric Human Multidrug Transporter ABCG2. Structure. 14(11). 1623–1632. 96 indexed citations

14.

Rothnie, Alice J., et al.. (2004). The Topography of Transmembrane Segment Six Is Altered during the Catalytic Cycle of P-glycoprotein. Journal of Biological Chemistry. 279(33). 34913–34921. 51 indexed citations

15.

Rosenberg, Mark F., et al.. (2003). Three-dimensional Structures of the Mammalian Multidrug Resistance P-glycoprotein Demonstrate Major Conformational Changes in the Transmembrane Domains upon Nucleotide Binding. Journal of Biological Chemistry. 278(10). 8294–8299. 165 indexed citations

16.

Taylor, Jenny C., D. Ferry, C. F. Higgins, & Richard Callaghan. (1999). The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. British Journal of Cancer. 81(5). 783–789. 13 indexed citations

17.

Callaghan, Richard & C. F. Higgins. (1995). Interaction of tamoxifen with the multidrug resistance P-glycoprotein. British Journal of Cancer. 71(2). 294–299. 97 indexed citations

18.

Callaghan, Richard. (1993). Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis. Hepatology. 18(1). 54–60. 1 indexed citations

19.

Callaghan, Richard, et al.. (1993). Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis. Hepatology. 18(1). 54–60. 12 indexed citations

20.

Callaghan, Richard, Alan R. Stafford, & Richard M. Epand. (1993). Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1175(3). 277–282. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact